Paladin Energy's Q1 FY2027 report shows uranium production at Langer Heinrich Mine was 1.00 million pounds, slightly down due to planned maintenance and ore characteristics, but sales rose to 1.16 million pounds at an average price of $79.4/lb amid rising uranium prices. The company signed a key agreement with Birch Narrows Dene Nation for its Patterson Lake South project in Canada and made progress on regulatory approvals. Exploration drilling extended uranium mineralisation at multiple sites, supporting resource growth. Paladin maintains its FY2027 production guidance and expects higher output in the second half of the year as mining advances and plant performance improves.
Paladin Energy Ltd's quarterly report is the subject, with Pluang's Basic Materials sector data for context. As of Oct 14, 2026 05:41 WIB, 29 of 62 US Basic Materials stocks rose, 33 fell. Notable movers include Standard Lithium Ltd at USD 1.45 (-3.02%), Equinox Gold Corp. at USD 10.90 (-2.68%), and Nutrien Ltd at USD 69.77 (+2.60%, 100% buy orders).
ZenaTech announced a 27.1% organic revenue growth in its Drone as a Service (DaaS) operations in 2026, driven by integrating AI and drones into surveying and inspection workflows. The company expects Q3 2026 revenues between C$13.4 million and C$14.8...
Nvidia CEO Jensen Huang has reaffirmed his long-standing forecast that global spending on AI infrastructure will surge to between $3 trillion and $4 trillion by 2030. This projection highlights the massive growth potential in the AI sector, driven by...
Targa Resources Corp. announced a quarterly cash dividend of $1.25 per common share for Q3 2026, payable on November 17, 2026, to shareholders of record as of October 30, 2026. The company will release its Q3 2026 financial results before market open...
Applied Materials projects sustained demand for its chipmaking equipment driven by AI infrastructure growth, expecting faster spending on wafer fab equipment through 2030. The company aims to increase its market share by over 2 percentage points from...
uniQure released 48-month data for its Huntington's disease drug AMT-130 showing a 44% slowing of disease progression, down from 75% at 36 months. This weaker result caused the stock to drop 37.3% in one day. The company had already submitted an FDA ...
